STOCK TITAN

Tenaya Therapeutics Inc - TNYA STOCK NEWS

Welcome to our dedicated news page for Tenaya Therapeutics (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tenaya Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tenaya Therapeutics's position in the market.

Rhea-AI Summary
Tenaya Therapeutics announces the first patient has been dosed with TN-201 gene therapy for the treatment of MYBPC3-associated HCM in a Phase 1b clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics announces publication of preclinical research on cardiac cellular regeneration in rodent models of chronic cardiac ischemic injury
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics to present TN-301 and TN-201 data at medical conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
conferences
Rhea-AI Summary
Tenaya Therapeutics CEO to participate in Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
conferences
-
Rhea-AI Summary
Tenaya Therapeutics reports financial results for Q2 2023 with a cash and investments balance of $152 million, providing funding into the first half of 2025. The company anticipates dosing the first patient in the Phase 1b trial of TN-201 in Q3 2023. TN-301 Phase 1 clinical trial data accepted for presentation at HFSA 2023. IND application for TN-401 gene therapy expected in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.5%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) to Present at 43rd Annual Canaccord Genuity Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
Rhea-AI Summary
Tenaya Therapeutics reports progress in clinical trials and expansion of advisory boards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.65%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.3%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Tenaya Therapeutics Inc

Nasdaq:TNYA

TNYA Rankings

TNYA Stock Data

350.18M
42.73M
1.53%
77.18%
3.93%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About TNYA

tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.